We studied in vitro ceftaroline combinations against 61 meticillin-resistant Staphylococcus aureus isolates; 18 of them were also resistant to linezolid, using overlapping E-test method. Daptomycin-ceftaroline combination obtained lower fractional inhibitory concentration values, in comparison with those including vancomycin or linezolid against meticillin-resistant S. aureus (P<0.05). All meticillin-and linezolid-resistant S. aureus strains were resistant to ceftaroline; nevertheless, combinations with vancomycin or daptomycin showed higher synergy or addition rates than those with linezolid.
INTRODUCTION
The attributable mortality of staphylococcal bacteraemia has significantly increased in the last few years due to an increasing number of elderly patients with more comorbidities and lower functional capacity (Yahav et al., 2016) . Currently, vancomycin remains the primary treatment option for managing meticillin-resistant Staphylococcus aureus (MRSA) bloodstream infections. Daptomycin is another treatment option that is often utilized in the setting of vancomycin treatment failures or when patients cannot tolerate vancomycin therapy and has been found to be associated with reduced clinical failure and 30-day mortality (Claeys et al., 2016) . Nevertheless, in serious situations (septic immunosuppressed patients), persistent infections (breakthrough or persistent bacteraemia) or those caused by multiresistant organisms, treatment options become limited, and combination regimens become preferred; however, the best agents to give in combination remain unknown.
There are three reasons to combine antimicrobial agents: increase the spectrum (especially in empiric therapy), obtain synergy and reduce regrowth of resistant strains (mainly targeted therapy). Growing clinical data support that b-lactam combinations offer potential advantages to standard therapy in MRSA bacteraemia including the safety profile by reducting the duration of bacteraemia (Tong et al., 2016) . It has been suggested that synergy results from a reduction in cell wall thickness caused by b-lactam exposure with a reduction in sequestration of the glycopeptide or lypopeptide, allowing increased access to their functional target (Barber et al., 2015; Holubar et al., 2016) .
Ceftaroline is a fifth-generation cephalosporin active against MRSA which is approved for complicated skin and soft tissue infections and community-acquired pneumonia (Sader et al., 2012; Frampton, 2013) . Its use has been reported as 'salvage' therapy for the treatment of complicated infections caused by MRSA with success rates over 50 % (Almirante et al., 2014; Sakoulas et al., 2014) . Ceftaroline has also been described as an alternative treatment in linezolid-resistant Staphylococcus epidermidis infections (Candel et al., 2015) . Although this resistance pattern is uncommon in S. aureus, a clinical outbreak of meticillin-and linezolid-resistant S. aureus (MLRSA) in Hospital Clínico San Carlos (S anchez García et al., 2010) led us to study the activity of ceftaroline alone and in combination against our MLRSA isolates. The aim of our study was to determine the in vitro synergy combinations of ceftaroline plus linezolid, daptomycin and vancomycin among MRSA and MLRSA isolates using the overlapping E-test method, a fast and clinically useful technique.
METHODS
For this study, we retrospectively collected 53 frozen MRSA from blood cultures and wound exudates, and 18 MLRSA from blood cultures and respiratory samples obtained from a clinical outbreak that occurred in our institution (Hospital Clínico San Carlos) 7 years ago (S anchez García et al., 2010) , harbouring a cfr-gene-mediated methyltransferase, which catalyses methylation of A2503 in the 23S rRNA gene of a large ribosomal subunit, conferring resistance to linezolid, chloramphenicol, pleuromutilins and clindamycin. Glass beads of all frozen S. aureus isolates were plated on Columbia sheep blood agar (COS; bioMeri eux) and CNA horse blood agar (CNA; bioMeri eux) and incubated overnight at 37 C. We identified isolates by mass spectrometry (Matrix-assisted laser desorption/ionization-time of flight, MALDI-TOF). Susceptibility testing was performed using the Vitek 2 system. Meticillin and linezolid resistance was confirmed by the Clinical and Laboratory Standards Institute (CLSI) interpretation of microdilution and E-test MIC results of oxacillin (R !4 mg l
À1
) and linezolid (R !4 mg l À1 ) (Morosini et al., 2012) . Activity of ceftaroline, vancomycin, daptomycin and linezolid alone and in combination was checked using the overlapping E-test method: the first antibiotic E-test (AB BIODISK) strip was placed on the agar plate, incubated for 1 h at room temperature and then replaced by a ceftaroline strip (Liofilchem) and placed on the same first E-test gradient. To evaluate the effect of combinations, we calculated the fractional inhibitory concentration (FIC) index, by measuring the antibiotic MICs obtained both each one (MICA and MICB) and combined (MICAB), according to the formula FIC=(MICAB/MICA)+(MICAB/MICB). Combinations were interpreted as synergistic (FIC 0.5), additive (FIC >0.5 to 1), indifferent (FIC >1 to 4) or antagonistic (FIC >4) (Tsuji & Rybak, 2006 
RESULTS AND DISCUSSION
Results in MRSA strains are summarized in Table 1 , and an example is shown in Fig. 1 . Synergy testing showed that combination of ceftaroline and daptomycin was synergistic Table 2 .
There are growing clinical data supporting that b-lactam combinations offer potential advantages to standard therapy in MRSA bacteraemia including the safety profile by reduction of the duration of bacteraemia (Tong et al., 2016) . The synergic effect observed in b-lactams and daptomycin combination is based on daptomycin properties. In the presence of physiological concentrations of calcium, daptomycin works as a cation, linking to anionic cell membrane. b-Lactams increase membrane cell exposure, improving the daptomycin linking. Although b-lactams preferentially bind PBP1, they can also bind some other PBP (Holubar et al., 2016) . CFT, ceftaroline; DPT, daptomycin; LNZ, linezolid; VAN, vancomycin.
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Ceftaroline has activity against MRSA due to its high-affinity binding to PBP2a. It exerts time-dependent killing and has a relatively prolonged post-antibiotic effect against S. aureus. Its optimal pharmacodynamic target should be fT > MIC (time interval during which free fraction of the drug concentrations are mantained above the minimum inhibitory concentration) greater than 50 %. This target is usually achieved against isolates with an MIC of 2 mg l À1 after administration of a dose of 600 mg every 12 h infused over 1 h. This antibiotic presents better lung diffusion than daptomycin or vancomycin and higher plasma concentrations than linezolid. Thus, it shows a more rapid bactericidal activity than vancomycin and linezolid (Minimal bactericidal concentration against S. aureus in 1, 2 and >64 µg ml À1 , respectively) (Saravolatz et al., 2010; Duplesis & Crum-Cianflone, 2011; Poon et al., 2012) . Experience in the use of ceftaroline for MRSA severe infections (endocarditis and bacteraemia) is increasing. However, there are about 50 reports published in the literature about successful 'salvage therapy' treatment of MRSA infections using combinations of ceftaroline and daptomycin with a success rate over 50 % (Almirante et al., 2014; Paladino et al., 2014; Sakoulas et al., 2014; Baxi et al., 2015; Cunha & Gran, 2015) . The indications for use of this combination usually were vancomycin MIC >2 µg ml Ceftaroline combinations against MRSA with either of them (Paladino et al., 2014; Baxi et al., 2015) , recurrent or persistent bacteraemia and toxicity. Combination was generally well tolerated. This powerful combination that was shown in our in vitro results and was described in the literature could allow early stabilization of patients and reduce the length of antimicrobial therapy in serious MRSA infections (Barber et al., 2015) . Since the MLRSA outbreak happened in our hospital, we have not registered any infection by this organism; therefore, we have not had the opportunity to try ceftaroline combinations. However, it could be an alternative against complex infections (bacteraemia and endocarditis) produced by this pathogen too. Based on our results, we can conclude that the combination ceftaroline-daptomycin was in vitro synergistic or additive in the majority of MRSA and MLRSA isolates studied.
Limitations of this study
Time-to-kill and chequerboard assays could not be performed, as antibiotic powders were not available. However, there are references about similarities of E-test results with those of chequerboard or time-to-kill assays (Balke et al., 2006) . Furthermore, E-test provides faster results, having a significant impact on clinical decisions.
